Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aranesp Sales Down As Physicians Adopt Wait-And-See Posture – Amgen

This article was originally published in The Pink Sheet Daily

Executive Summary

Nineteen percent decline in U.S. sales of the erythropoiesis-stimulating agent versus Q2 2006 is a response to labeling change, regulatory climate, Amgen exec says.

You may also be interested in...



Amgen Says 2007 Profits Will Top October Projections

California biotech cites cost-cutting measures as reason for upgraded earnings per share guidance of $4.30.

Amgen Says 2007 Profits Will Top October Projections

California biotech cites cost-cutting measures as reason for upgraded earnings per share guidance of $4.30.

Amgen Halts Construction On Manufacturing Plant In Ireland

The planned multi-product facility would have manufactured “drugs in the pipeline,” Amgen tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel